Evidence map›Paper›PMID 39154783›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2024

Squamoid Eccrine Ductal Carcinoma Displays Ultraviolet Mutations and Intermediate Gene Expression Relative to Squamous Cell Carcinoma, Microcystic Adnexal Carcinoma, and Porocarcinoma.

Paul W Harms, Mason Runge, May P Chan, Chia-Jen Liu, Zhaoping Qin, Francis Worden, Dan R Robinson, Arul M Chinnaiyan, Scott A Mclean, Kelly L Harms and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Paul W HarmsDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan; Rogel Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan. Electronic address: paulharm@med.umich.edu.
Mason RungeDepartment of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.
May P ChanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.
Chia-Jen LiuDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan.
Zhaoping QinDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Francis WordenRogel Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Dan R RobinsonDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan.
Arul M ChinnaiyanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Rogel Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan; Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan.
Scott A McleanDepartment of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Kelly L HarmsDepartment of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.
Douglas R FullenDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.
Rajiv M PatelDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan; Cutaneous Pathology, WCP Laboratories, Inc, Maryland Heights, Missouri.
Aleodor A AndeaDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan; Roswell Park Comprehensive Cancer Center, Buffalo, New York, New York.
Aaron M UdagerDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; Rogel Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan; Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan.

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
NCI NIH HHS P30 CA046592
6 · The paper itself

Abstract

Squamoid eccrine ductal carcinoma is a rare infiltrative tumor with morphologic features intermediate between squamous cell carcinoma (SCC) and sweat gland carcinomas such as microcystic adnexal carcinoma. Although currently classified as a sweat gland carcinoma, it has been debated whether squamoid eccrine ductal carcinoma is better classified as a variant of SCC. Furthermore, therapeutic options for patients with advanced disease are lacking. Here, we describe clinicopathologic features of a cohort of 15 squamoid eccrine ductal carcinomas from 14 unique patients, with next-generation sequencing DNA profiling for 12 cases. UV signature mutations were the dominant signature in the majority of cases. TP53 mutations were the most highly recurrent specific gene alteration, followed by mutations in NOTCH genes. Recurrent mutations in driver oncogenes were not identified. By unsupervised comparison of global transcriptome profiles in squamoid eccrine ductal carcinoma (n = 7) to SCC (n = 10), porocarcinoma (n = 4), and microcystic adnexal carcinoma (n = 4), squamoid eccrine ductal carcinomas displayed an intermediate phenotype between SCC and sweat gland tumors. Squamoid eccrine ductal carcinoma displayed significantly higher expression of 364 genes (including certain eccrine markers) and significantly lower expression of 525 genes compared with other groups. Our findings support the classification of squamoid eccrine ductal carcinoma as a carcinoma with intermediate features between SCC and sweat gland carcinoma.

Indexed as

Carcinoma, Squamous CellEccrine PorocarcinomaMutationSweat Gland NeoplasmsAgedAged, 80 and overBiomarkers, TumorCarcinoma, DuctalFemaleHumansMaleMiddle AgedNeoplasms, Adnexal and Skin AppendageSkin NeoplasmsTranscriptomeUltraviolet RaysBiomarkers, Tumoradnexal carcinomamicrocystic adnexal carcinomaporocarcinomasquamoid eccrine ductal carcinomasquamous cell carcinomaTP53tumor sequencingultraviolet mutation

Identifiers

PMID39154783
PMCPMC11585436

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.